PURPOSE: TOURÔ is a multicenter study designed to characterize infection types, pathogens, and outcomes of patients treated with telavancin (TLV) in clinical practice through retrospective medical chart review. Telavancin is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). In the US, Canada, and Russia, TLV is approved for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) when alternative treatments are not suitable. In the European Union, TLV is approved as an alternative treatment for HABP suspected to be caused by MRSA. Telavancin also demonstrated comparable efficacy to vancomycin in a limited number of patients with HABP/VABP and concurrent S. aureus bacteremia.

No abstract